-
Coccidioidal infections are always unique the travel history often provides the right clue for the practitioner but first you have to think to ask the right question.
-
In a prospective observational study, investigators of the HIV-CAUSAL Collaboration evaluated data from participating HIV clinics in Europe and the U.S. Veterans Administration system to determine the optimal CD4+ T cell count at which combination antiretroviral therapy (cART) should be initiated.
-
GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18] Vaccine, Recombinant) previously received FDA approval for prevention of cervical, vulvar, and vaginal cancer and associated precancerous lesions, and for prevention of genital warts in males and females 9-26 years of age.
-
A retrospective study was conducted of 563 children who presented over the last decade to two pediatric immunodeficiency centers in the United Kingdom.
-
ZOSTAVAX®, which had previously received FDA approval for prevention of herpes zoster (HZ) and post-herpetic neuralgia in individuals 60 years of age and older, had its approval extended to include people 50-59 years of age on March 24, 2011.
-
Can the informed consent process actually provide too much information? That's the contention of HIV researcher Susan Allen, MD, MPH, who points to a recent study she tried to conduct in Zambia of participants' knowledge about contraceptive options.
-
Men and women infected with HIV dramtically reduced the risk of transmitting the virus to their sexual partners through initiation of oral antiretroviral therapy (ART), according to findings from a large multinational clinical study conducted by the HIV Prevention Trials Network (HPTN).
-
Elite suppressors are that 1% or fewer of HIV patients who do not develop signs of disease progression despite living for years without treatment.
-
HIV research increasingly points to a connection between CD8 T cells and suppressed virus, but precisely how this works remains a mystery.
-
Investigators studying "elite suppressors," this unique group of HIV-infected individuals who can ward off illness from HIV for years or even decades, have found clues that might lead to powerful new treatments.